Business Context and Reporting Period
Company: InMed Pharmaceuticals Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 14, 2022
Reporting Period: Second quarter of fiscal year 2022, ended December 31, 2021.
Context: The filing serves as a Regulation FD disclosure to announce financial results for the specified quarter. The company is an emerging growth company incorporated in British Columbia, Canada, with common shares trading on The Nasdaq Stock Market LLC under the symbol "INM".
Key Financial Metrics
The provided text is a cover page and index for the 8-K filing. It references the announcement of financial results but does not contain the specific numerical data within the text body.
- Revenue: Not provided in this text.
- Profit/Loss: Not provided in this text.
- Cash Flow: Not provided in this text.
- Margins: Not provided in this text.
- Debt and Liquidity: Not provided in this text.
Note: Specific financial figures are contained in the referenced news release (Exhibit 99.1), which is not included in the input text.
Material Changes
The filing text does not provide specific data to compare against the prior comparable period. It only confirms that results for the second quarter of fiscal 2022 were announced.
Guidance, Outlook, and Risks
Management Commentary: The filing indicates that financial results were announced on February 14, 2022. No specific commentary, guidance, or outlook is detailed in the provided text.
Risks and Contingencies: No specific risks or contingencies are described in this excerpt.
Unusual Items: None identified in the provided text.
Investor Verification Checklist
- Review Exhibit 99.1 (News release dated February 14, 2022) to obtain the actual revenue, net loss, and cash position figures for the quarter ended December 31, 2021.
- Verify the company's status as an emerging growth company and any associated election regarding extended transition periods for accounting standards.
- Confirm the trading symbol (INM) and exchange (Nasdaq) for accurate market data tracking.
- Check subsequent filings for any updates to the financial results announced in this 8-K.